- Home
- NCI vs ACXP Comparison
NCI vs ACXP Comparison
Compare NCI & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCI
- ACXP
- Stock Information
- Founded
- NCI 1992
- ACXP 2017
- Country
- NCI Hong Kong
- ACXP United States
- Employees
- NCI N/A
- ACXP N/A
- Industry
- NCI
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- NCI
- ACXP Health Care
- Exchange
- NCI NYSE
- ACXP Nasdaq
- Market Cap
- NCI N/A
- ACXP 8.4M
- IPO Year
- NCI 2024
- ACXP 2021
- Fundamental
- Price
- NCI $0.35
- ACXP $0.38
- Analyst Decision
- NCI
- ACXP Strong Buy
- Analyst Count
- NCI 0
- ACXP 1
- Target Price
- NCI N/A
- ACXP $12.00
- AVG Volume (30 Days)
- NCI 99.7K
- ACXP 107.1K
- Earning Date
- NCI 05-21-2025
- ACXP 05-13-2025
- Dividend Yield
- NCI N/A
- ACXP N/A
- EPS Growth
- NCI N/A
- ACXP N/A
- EPS
- NCI 0.08
- ACXP N/A
- Revenue
- NCI $22,481,862.00
- ACXP N/A
- Revenue This Year
- NCI N/A
- ACXP N/A
- Revenue Next Year
- NCI N/A
- ACXP N/A
- P/E Ratio
- NCI $4.17
- ACXP N/A
- Revenue Growth
- NCI N/A
- ACXP N/A
- 52 Week Low
- NCI $0.28
- ACXP $0.30
- 52 Week High
- NCI $1.80
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- NCI N/A
- ACXP 44.94
- Support Level
- NCI N/A
- ACXP $0.34
- Resistance Level
- NCI N/A
- ACXP $0.44
- Average True Range (ATR)
- NCI 0.00
- ACXP 0.02
- MACD
- NCI 0.00
- ACXP 0.00
- Stochastic Oscillator
- NCI 0.00
- ACXP 37.35
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.